ATL awaits FDA extension of breast PMA

Article

ATL chairman and CEO Dennis Fill this month said he expects theFood and Drug Administration to approve within the next severalweeks the use of the company's flagship HDI 3000 scanner for differentiatingmalignant from benign solid breast lesions. ATL, of

ATL chairman and CEO Dennis Fill this month said he expects the

Food and Drug Administration to approve within the next several

weeks the use of the company's flagship HDI 3000 scanner for differentiating

malignant from benign solid breast lesions. ATL, of Bothell, WA,

already has FDA approval to differentiate solid breast lesions

using its older Ultramark 9 HDI scanner, and filed a supplemental

premarket approval application with the agency to extend the technique

to HDI 3000 (SCAN 4/24/96). Fill made the comments during a presentation

at the Bear Stearns Health Care Conference in New York City.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.